Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on May 14, 2025
GENFIT : Publication du rapport de performance extra-financière 2025 (exercice 2024)
GlobeNewswire
·
May 14, 2025
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 14 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le …
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
GlobeNewswire
·
May 14, 2025
Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026 $151.3 million in cash, cash equivalents, and short-term investments supports projected operations into 2027 SAN …
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
GlobeNewswire
·
May 14, 2025
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has engaged Veloxity …
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025
GlobeNewswire
·
May 14, 2025
PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
– Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for ABP-450, which offers potential …
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
GlobeNewswire
·
May 14, 2025
First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million …
STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
GlobeNewswire
·
May 14, 2025
HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic …
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to enter the clinic in second half of 2025, with interim …
BioCardia Reports First Quarter 2025 Business Highlights and Financial Results
GlobeNewswire
·
May 14, 2025
SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of …
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexible Maintenance Dosing - - Multiple Milestones Achieved by …
Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Tenax …
Codexis Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 14, 2025
Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming TIDES USA annual meeting, including three from leading …
Korro to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 14, 2025
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital Markets Global Healthcare Conference Ram …
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights
GlobeNewswire
·
May 14, 2025
- Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD - Presented the first human data mapping cell-level transduction and aflibercept mRNA expression 3 …
Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress
GlobeNewswire
·
May 14, 2025
Expanded life science and industrial portfolio with six additional life science products in development Advances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme markets Up to $4.5 million …
Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th
GlobeNewswire
·
May 14, 2025
MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform …
Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine
GlobeNewswire
·
May 14, 2025
Challenge Study measured safety, efficacy against infection and symptomatic disease as well as viral shedding Machine learning analyses identified statistically significant correlates of protection and will be incorporated into the development of Vaxart’s …
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
GlobeNewswire
·
May 14, 2025
SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of …
BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 14, 2025
MELVILLE, N.Y., May 14, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results …
Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia
GlobeNewswire
·
May 14, 2025
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the Phase I COVALENT-103 trial of BMF-500 in …